About Vaccine for COVID-19
Bivalent Boosters by appointment every other Friday in Downieville and Loyalton
- Schedule an appointment directly through MyTurn: Loyalton | Downieville
- Assistance over the phone: 1-833-422-4255 M-F 8AM-8PM, Sa-Su 8AM-5PM
On August 31, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following a primary or booster dose with any authorized or approved monovalent COVID-19 vaccine. The bivalent vaccines, which we will also refer to as “updated boosters,” contain two messenger RNA (mRNA) components of SARS-CoV-2 virus, one of the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2.
The Moderna COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 18 years of age and older. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 12 years of age and older. With this most recent authorization, the original monovalent mRNA COVID-19 vaccines are no longer authorized as booster doses for individuals 12 years of age and older. The FDA will work quickly to evaluate future data and submissions to support authorization of bivalent COVID-19 boosters for additional age groups.
There are many options for scheduling a COVID-19 Vaccination:
- Vaccine Finder or call 800-232-0233
- Your Health Care Provider: Tahoe Forest Hospital, Eastern Plumas Health Care, Western Sierra Medical Clinic, Renown Health, St. Mary's Hospital, etc.
- Veterans Services
- Pharmacies: Albertsons, CVS, Rite Aid, Sam’s Club, Safeway, Smiths, Walgreens, Walmart
- My Turn or call 1-833-422-4255 (M-F 8AM - 8PM, Sa-Su 8AM-5PM) for assistance.
- GETVAX: Text your zip code to 438829 and three locations will be texted back to you. Contact locations to schedule.
Updated Interim Clinical Considerations
CDC has issued updated Interim Clinical Considerations regarding booster doses of COVID-19 vaccines, as well as new guidance for vaccination in children ages 6 months and older. The Western States Scientific Safety Review Workgroup released a statement affirming these updates.
Second Booster Shot for Some Individuals
Based on expanded FDA EUAs, the following individuals may receive a second booster dose at least four months after their first booster dose:
- A first booster dose for children aged 5-11
- People 12 years and older who are moderately or severely immunocompromised
- People 50 years and older who are not moderately or severely immunocompromised
- People 18-49 years old who are not moderately or severely immunocompromised and who received Janssen COVID-19 vaccine as both their primary series dose and booster dose
- COVID-19 Booster Vaccines
- COVID-19 Vaccine Booster Questions & Answers
- Get the Facts on COVID-19 Vaccines, Boosters , and Additional Doses
- FACT SHEET: Pfizer COVID-19 Vaccine (Comirnaty)Benefits and Risks (PDF)
- FACT SHEET: Johnson & Johnson COVID-19 VaccineBenefits and Risk
- FACT SHEET: Moderna COVID-19 Vaccine (Spikevax)Benefits and Risks
COVID-19 Vaccines While Pregnant or Breastfeeding
COVID-19 vaccination is recommended for all people aged 5 years and older, including people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. Pregnant and recently pregnant people are more likely to get severely ill with COVID-19 compared with non-pregnant people. Getting a COVID-19 vaccine can protect you from severe illness from COVID-19. What You Need to Know, Vaccination During Pregnancy Guidance (ca.gov).
Where do I report a reaction to a vaccination?
Report an adverse event to VAERS -Vaccine Adverse Event Reporting System. VAERS is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a report to VAERS, including parents and patients.